Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Weight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug ...